Form 4 for BMRN BIOMARIN PHARMACEUTICAL INC
Accepted 2022-01-14 00:00:00 ET · period of report 2021-12-21 · accession 0001567619-22-001225 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-01-14 | 2022-01-12+ | BMRN | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale+OE | $88.43 | -10.0K | 303.8K | -3% | -$884.3K |
| D | 2022-01-14 | 2021-12-21 | BMRN | BIENAIME JEAN JACQUES | CEO, Dir | L - Small Acq | $89.22 | +100 | 303.8K | +0.0% | +$8,922 |
| DM | 2022-01-14 | 2022-01-12+ | BMRN | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $37.46 | +10.0K | 308.8K | +3% | +$374.6K |
| DM | 2022-01-14 | 2022-01-12+ | BMRN | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $0.00 | -10.0K | 115.0K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-13 | S | D | 5,000 | $87.86 | 303,789 | D | — | — | (F1) Trade made pursuant to a 10b5-1 plan executed on October 13, 2021. |
| 2 | Common | Common Stock | 2021-12-21 | L | A | 100 | $89.22 | 303,789 | D | — | — | |
| 3 | Common | Common Stock | 2022-01-12 | M | A | 5,000 | $37.46 | 308,789 | D | — | — | (F1) Trade made pursuant to a 10b5-1 plan executed on October 13, 2021. |
| 4 | Common | Common Stock | 2022-01-12 | S | D | 5,000 | $89.00 | 303,789 | D | — | — | (F2) The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 50 shares, with the reporting person's purchase of shares at a price of $78.7700 on September 9, 2021. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. (F1) Trade made pursuant to a 10b5-1 plan executed on October 13, 2021. |
| 5 | Common | Common Stock | 2022-01-13 | M | A | 5,000 | $37.46 | 308,789 | D | — | — | (F1) Trade made pursuant to a 10b5-1 plan executed on October 13, 2021. |
| 6 | Derivative | Stock Option (Right to buy Common Stock) | 2022-01-12 | M | D | 5,000 | $0.00 | 120,000 | D | $37.46 · 2012-11-08 to 2022-05-07 | 5,000 Common Stock | (F1) Trade made pursuant to a 10b5-1 plan executed on October 13, 2021. (F3) Reflects the number of options outstanding after the transactions from this specific stock option grant. |
| 7 | Derivative | Stock Option (Right to buy Common Stock) | 2022-01-13 | M | D | 5,000 | $0.00 | 115,000 | D | $37.46 · 2012-11-08 to 2022-05-07 | 5,000 Common Stock | (F1) Trade made pursuant to a 10b5-1 plan executed on October 13, 2021. (F3) Reflects the number of options outstanding after the transactions from this specific stock option grant. |